by Clinical Neuropsychologist Online | Wednesday, April 17, 2024 | Dementia
Abstract INTRODUCTION In trials of amyloid-lowering drugs for Alzheimer’s disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron emission...
by Clinical Neuropsychologist Online | Tuesday, April 16, 2024 | Dementia
Abstract INTRODUCTION Ozone (O3) is an air pollutant associated with Alzheimer’s disease (AD) risk. The lung–brain axis is implicated in O3-associated glial and amyloid pathobiology; however, the role of disease-associated astrocytes (DAAs) in this process...
by Clinical Neuropsychologist Online | Tuesday, April 16, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is characterized by cognitive impairments; however, heightened anxiety often accompanies and, in some cases, exacerbates cognitive its. The present study aims to understand the influence of multiple variables on...
by Clinical Neuropsychologist Online | Tuesday, April 16, 2024 | Dementia
Abstract INTRODUCTION Effective longitudinal biomarkers that track disease progression are needed to characterize the presymptomatic phase of genetic frontotemporal dementia (FTD). We investigate the utility of cerebral perfusion as one such biomarker in...
by Clinical Neuropsychologist Online | Tuesday, April 16, 2024 | Dementia
Dementia, Volume 23, Issue 5, Page 850-881, July 2024. Young-onset dementia (YOD) affects individuals under 65 years of age, often leading to loss of employment and independence. Families provide increasing levels of care to family members with YOD, resulting in...
